36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details


臨床試験数 : 160 薬物数 : 195 - (DrugBank : 47) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 124

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-001967-35-AT
(EUCTR)
19/07/201628/06/2016A study to assess the efficacy of a vitamin D-containing ointment applied on the skin to improve wound healing in butterfly childrenA double-blind, placebo-controlled cross-over study to assess the efficacy of topical calcipotriol (Psorcutan®-ointment containing 0.05 µg/g calcipotriol) to improve wound healing in dystrophic epidermolysis bullosa (DEB) - Topical calcipotriol in DEB Subjects with dystrophic epidermolysis bullosa (DEB) with a known mutation in the type VII collagen gene.
MedDRA version: 19.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Psorcutan-Ointment
INN or Proposed INN: CALCIPOTRIOL
Universitätsklinik für Dermatologie, Paracelsus medizinische Privatuniversität SalzburgNULLNot RecruitingFemale: yes
Male: yes
15Phase 2Austria